Cancer Immunotherapeutics: Evolution of Monoclonal Antibodies to Peptide Immunogens

Koprowski H : First decade (1950–1960) of studies and trials with the polio vaccine. Biologicals, 2006; 34:81–86. Epub 2006 May 2008.

Koprowski H , Steplewski Z , Herlyn D , and Herlyn M : Study of antibodies against human melanoma produced by somatic cell hybrids. Proc Natl Acad Sci USA, 1978; 75:3405–3409.

Sears HF , Atkinson B , Mattis J , Ernst C , Herlyn D , Steplewski Z , Hayry P , and Koprowski H : Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet, 1982; 1:762–765.

Advani AS : New immune strategies for the treatment of acute lymphoblastic leukemia: antibodies and chimeric antigen receptors. Am Soc Hematol Educ, 2013; 131-7.:10.1182/asheducation-2013.1181.1131.

Litzow MR : Monoclonal antibody-based therapies in the treatment of acute lymphoblastic leukemia. Am Soc Clin Oncol Educ, 2013; 33:294-9.:10.1200/EdBook_AM.2013.1233.1294.

Akerst SN , Riebandt G , Miller A , Groman A , Odunsi K , and Lele S : Bevacizumab for the treatment of recurrent ovarian cancer: a retrospective cohort study. Eur J Gynaecol Oncol, 2013; 34:113–119.

Koprowski H , Herlyn D , Lubeck M , DeFreitas E , and Sears HF : Human anti-idiotype antibodies in cancer patients: Is the modulation of the immune response beneficial for the patient?. Proc Natl Acad Sci USA, 1984; 81:216–219.

Herlyn D , Wettendorff M , Iliopoulos D , and Koprowski H : Functional mimicry of tumor-associated antigens by antiidiotypic antibodies. Exp Clin Immunogenet, 1988; 5:165–175.

Hatzubai A , Maloney DG , and Levy R : The use of a monoclonal anti-idiotype antibody to study the biology of a human B cell lymphoma. J Immunol, 1981; 126:2397–2402.

Herlyn D , Wettendorff M , Schmoll E , Iliopoulos D , Schedel I , Dreikhausen U , Raab R , Ross AH , Jaksche H , Scriba M , and Koprowski H : Anti-idiotype immunization of cancer patients: modulation of the immune response. Proc Natl Acad Sci USA, 1987; 84:8055–8059.

Cheung NK , Guo HF , Heller G , and Cheung IY : Induction of Ab3 and Ab3′ antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma. Clin Cancer Res, 2000; 6:2653–2660.

Schultes BC , Baum RP , Niesen A , Noujaim AA , and Madiyalakan R : Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunol Immunother, 1998; 46:201–212.

Lode HN , Schmidt M , Seidel D , Huebener N , Brackrock D , Bleeke M , Reker D , Brandt S , Mueller HP , Helm C , and Siebert N : Vaccination with anti-idiotype antibody ganglidiomab mediates a GD(2)-specific anti-neuroblastoma immune response. Cancer Immunol Immunother, 2013; 62:999–1010. doi:1010.1007/s00262-00013-01413-y. Epub 02013 Apr 00217.

Verrill H , Goldberg M , Rosenbaum R , Abbott R , Simunovic L , Steplewski Z , and Koprowski H : Clinical trial of Wistar Institute 17-1A monoclonal antibody in patients with advanced gastrointestinal adenocarcinoma: a preliminary report. Hybridoma, 1996; 5:S175–183.

Tempero MA , Sivinski C , Steplewski Z , Harvey E , Klassen L , and Kay HD : Phase II trial of interferon gamma and monoclonal antibody 17-1A in pancreatic cancer: biologic and clinical effects. J Clin Oncol, 1990; 8:2019–2026.

Makower D , Sparano JA , Wadler S , Fehn K , Landau L , Wissel P , Versola M , and Mani S : A pilot study of edrecolomab (Panorex, 17-1A antibody) and capecitabine in patients with advanced or metastatic adenocarcinoma. Cancer Invest, 2003; 21:177–184.

Faillot T , Magdelenat H , Mady E , Stasiecki P , Fohanno D , Gropp P , Poisson M , and Delattre JY : A phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas. Neurosurgery, 1996; 39:478–483.

Robert F , Ezekiel MP , Spencer SA , Meredith RF , Bonner JA , Khazaeli MB , Saleh MN , Carey D , LoBuglio AF , Wheeler RH , Cooper MR , and Waksal HW : Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol, 2001; 19:3234–3243.

Thurin J , Thurin M , Kimoto Y , Herlyn M , Lubeck MD , Elder DE , Smereczynska M , Karlsson KA , Clark WM Jr , Steplewski Z , and Koprowski H : Monoclonal antibody-defined correlations in melanoma between levels of GD2 and GD3 antigens and antibody-mediated cytotoxicity. Cancer Res, 1987; 47:1229–1233.

Blaszczyk-Thurin M , Thurin J , Hindsgaul O , Karlsson KA , Steplewski Z , and Koprowski H : Y and blood group B type 2 glycolipid antigens accumulate in a human gastric carcinoma cell line as detected by monoclonal antibody. Isolation and characterization by mass spectrometry and NMR spectroscopy. J Biol Chem, 1987; 262:372–379.

Herlyn M , and Koprowski H : Melanoma antigens: immunological and biological characterization and clinical significance. Annu Rev Immunol, 1988; 6:283–308.

Tai T , Cahan LD , Tsuchida T , Saxton RE , Irie RF , and Morton DL : Immunogenicity of melanoma-associated gangliosides in cancer patients. Int J Cancer, 1985; 35:607–612.

Iliopoulos D , Ernst C , Steplewski Z , Jambrosic JA , Rodeck U , Herlyn M , Clark WH Jr , Koprowski H , and Herlyn D : Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides. J Natl Cancer Inst, 1989; 81:440–444.

Yu AL , Gilman AL , Ozkaynak MF , London WB , Kreissman SG , Chen HX , Smith M , Anderson B , Villablanca JG , Matthay KK , Shimada H , Grupp SA , Seeger R , Reynolds CP , Buxton A , Reisfeld RA , Gillies SD , Cohn SL , Maris JM , and Sondel PM : Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med, 2010; 363:1324–1334. doi:1310.1056/NEJMoa0911123.

Shetye J , Christensson B , Rubio C , Rodensjo M , Biberfeld P , and Mellstedt H : The tumor-associated antigens BR55-2, GA73-3 and GICA 19-9 in normal and corresponding neoplastic human tissues, especially gastrointestinal tissues. Anticancer Res, 1989; 9:395–404.

Steplewski Z , Lubeck MD , Scholz D , Loibner H , McDonald Smith J , and Koprowski H : Tumor cell lysis and tumor growth inhibition by the isotype variants of MAb BR55-2 directed against Y oligosaccharide. In Vivo, 1991; 5:79–83.

Kitamura K , Stockert E , Garin-Chesa P , Welt S , Lloyd KO , Armour KL , Wallace TP , Harris WJ , Carr FJ , and Old LJ : Specificity analysis of blood group Lewis-y (Le(y)) antibodies generated against synthetic and natural Le(y) determinants. Proc Natl Acad Sci USA, 1994; 91:12957–12961.

Pichla SL , Murali R , and Burnett RM : Preliminary crystallographic data for an Fab to the melanoma-associated GD2 ganglioside, and the purification of a soluble form of this antigen. Acta Crystallogr D Biol Crystallogr, 1995; 51:124–126.

Pichla SL , Murali R , and Burnett RM : The crystal structure of a Fab fragment to the melanoma-associated GD2 ganglioside. J Struct Biol, 1997; 119:6–16.

Taylor JS , and Burnett RM : DARWIN: a program for docking flexible molecules. Proteins, 2000; 41:173–191.

Blaszczyk-Thurin M , Murali R , Westerink MA , Steplewski Z , Co MS , and Kieber-Emmons T : Molecular recognition of the Lewis Y antigen by monoclonal antibodies. Protein Eng, 1996; 9:447–459.

Murali R , and Kieber-Emmons T : Molecular recognition of a peptide mimic of the Lewis Y antigen by an anti-Lewis Y antibody. J Mol Recognit, 1997; 10:269–276.

Luo P , Canziani G , Cunto-Amesty G , and Kieber-Emmons T : A molecular basis for functional peptide mimicry of a carbohydrate antigen. J Biol Chem, 2000; 275:16146–16154.

Pashov A , Perry M , Dyar M , Chow M , and Kieber-Emmons T : Carbohydrate mimotopes in the rational design of cancer vaccines. Curr Top Med Chem, 2005; 5:1171–1185.

Kieber-Emmons T , Luo P , Qiu J , Chang TYOI , Blaszczyk-Thurin M , and Steplewski Z : Vaccination with carbohydrate peptide mimotopes promotes anti-tumor responses. Nat Biotechnol, 1999; 17:660–665.

Qiu J , Luo P , Wasmund K , Steplewski Z , and Kieber-Emmons T : Towards the development of peptide mimotopes of carbohydrate antigens as cancer vaccines. Hybridoma, 1999; 18:103–112.

Kieber-Emmons T , Monzavi-Karbassi B , Pashov A , Saha S , Murali R , and Kohler H : The promise of the anti-idiotype concept. Front Oncol, 2012; 2:196.:10.3389/fonc.2012.00196. eCollection 02012.

Pashov A , Monzavi-Karbassi B , and Kieber-Emmons T : Immune surveillance and immunotherapy: lessons from carbohydrate mimotopes. Vaccine, 2009; 27:3405–3415. doi: 3410.1016/j.vaccine.2009.3401.3074. Epub 2009 Feb 3405.

Monzavi-Karbassi B , Hennings LJ , Artaud C , Liu T , Jousheghany F , Pashov A , Murali R , Hutchins LF , and Kieber-Emmons T : Preclinical studies of carbohydrate mimetic peptide vaccines for breast cancer and melanoma. Vaccine, 2007; 25:3022–3031. Epub 2007 Jan 3026.

Wondimu A , Zhang T , Kieber-Emmons T , Gimotty P , Sproesser K , Somasundaram R , Ferrone S , Tsao CY , and Herlyn D : Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice. Cancer Immunol Immunother, 2008; 57:1079–1089.